See more : Shree Bhavya Fabrics Limited (SBFL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Inozyme Pharma, Inc. (INZY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Inozyme Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Canada Silver Cobalt Works Inc. (CCWOF) Income Statement Analysis – Financial Results
- Hamilton Lane Incorporated (HLNE) Income Statement Analysis – Financial Results
- ACRES Commercial Realty Corp. (ACR-PC) Income Statement Analysis – Financial Results
- Pritish Nandy Communications Ltd (PNC.NS) Income Statement Analysis – Financial Results
- C-Lab Ltd (CLAB.TA) Income Statement Analysis – Financial Results
Inozyme Pharma, Inc. (INZY)
About Inozyme Pharma, Inc.
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.29M | 1.18M | 1.05M | 217.00K | 83.00K | 26.00K |
| Gross Profit | -1.29M | -1.18M | -1.05M | -217.00K | -83.00K | -26.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 54.85M | 47.85M | 37.72M | 46.49M | 16.22M | 8.10M |
| General & Administrative | 20.80M | 20.83M | 18.93M | 10.55M | 4.59M | 3.49M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.80M | 20.83M | 18.93M | 10.55M | 4.59M | 3.49M |
| Other Expenses | 0.00 | -319.00K | -189.00K | 247.00K | -24.00K | 4.35M |
| Operating Expenses | 75.65M | 68.68M | 56.65M | 57.04M | 20.81M | 11.59M |
| Cost & Expenses | 75.65M | 68.68M | 56.65M | 57.04M | 20.81M | 11.59M |
| Interest Income | 7.84M | 1.93M | 211.00K | 370.00K | 1.11M | 284.00K |
| Interest Expense | 3.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 833.00K | 1.18M | 1.05M | 217.00K | 83.00K | 26.00K |
| EBITDA | -74.81M | -65.88M | -55.97M | -56.82M | -20.72M | -11.57M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -75.65M | -68.68M | -56.65M | -57.04M | -20.81M | -11.59M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.48M | 1.61M | 22.00K | 617.00K | 1.08M | 4.63M |
| Income Before Tax | -71.17M | -67.06M | -56.62M | -56.42M | -19.72M | -6.96M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.61M | -211.00K | -587.00K | -1.11M | 4.63M |
| Net Income | -71.17M | -65.45M | -56.41M | -55.84M | -18.62M | -6.96M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.37 | -1.73 | -2.39 | -2.39 | -1.23 | -0.46 |
| EPS Diluted | -1.37 | -1.73 | -2.39 | -2.39 | -1.23 | -0.46 |
| Weighted Avg Shares Out | 51.84M | 37.76M | 23.56M | 23.38M | 15.16M | 15.14M |
| Weighted Avg Shares Out (Dil) | 51.84M | 37.76M | 23.56M | 23.38M | 15.16M | 15.14M |
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Matt Winton, Ph.D.,...
Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks
Inozyme Pharma (INZY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Inozyme Pharma to Present at Upcoming Investor Conferences
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced Doug Treco, Ph.D., CEO...
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 –
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
- INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing hemodialysis; low PPi levels are associated with calciphylaxis, a rare, life-threatening complication of ESKD -
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024
BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that interim data from the...
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors
BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced the appointment of Erik Harris...
Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look'
Stifel initiated coverage on Inozyme Pharma Inc. INZY, saying, “This under-the-radar stock could be worth a look ahead of it.”
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Matt Winton, Ph.D.,...
Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion
Inozyme Pharma, Inc. interim data from the phase 1 SEAPORT-1 study, using INZ-701 for the treatment of patients with end-stage kidney disease with hemodialysis with calciphylaxis, expected Q4 of 2024. Fast Track Designation given by the FDA for the use...
Source: https://incomestatements.info
Category: Stock Reports